What was reported
Public Chinese-language coverage described Chalupsky's long multiple myeloma journey and his decision to seek CAR-T-related care in Shanghai. Reports linked the story to Ruijin Hospital and Shanghai's cell-therapy capabilities.
What the story does not prove
A public media profile does not mean the same pathway is available or appropriate for another patient. CAR-T decisions depend on disease subtype, prior treatments, organ function, infection risk, product access, physician judgment, and timing.
Questions patients should ask
A realistic inquiry should ask whether the center can review records remotely, what tests must be repeated in China, expected hospitalization length, total self-pay ranges, caregiver needs, visa timing, and follow-up plans after returning home.